Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVI.bf

Imaging: Tumoral cavitation

Publications

Interiano RB, McCarville MB, Wu J, Davidoff AM, Sandoval J, Navid F

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.

Journal of pediatric surgery. 2015;50(9):1484-9

Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N

New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Cancer imaging : the official publication of the International Cancer Imaging Society. 2014;14(1):26

Nishinari Y, Kashiwaba M, Umemura A, Komatsu H, Sasaki A, Wakabayashi G

Pulmonary hilar lymph node metastasis of breast cancer induced bronchopleural fistula and superior vena cava syndrome.

The American journal of case reports. 2014;15:492-5

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Cancer imaging : the official publication of the International Cancer Imaging Society. 2012;12(1):225-35

Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(5):1111-1120

Kelly RJ, Hnatiuk O, Giaccone G

Antiangiogenesis induced tumor cavitation in lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(12):1573-5

Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(9):1405-12

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(11):2184-91